Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAL-05CR is an injectable, intra-articular sustained-release formulation developed for the treatment of moderate to severe osteoarthritis pain. It utilizes verapamil, a calcium channel blocker, embedded in biodegradable polymer microspheres to provide continuous local delivery directly within the joint. The mechanism of action involves regulation of calcium ion channels implicated in osteoarthritis degeneration; by interfering with these channels, verapamil reduces the release of harmful enzymes and inflammation, thereby preserving joint function and providing long-lasting pain relief. This approach aims to minimize systemic side effects and reduce injection frequency compared to traditional therapies[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CAL-05CR.